IRIX vs PATH · rev $12.6M vs P/E 19, rev $1.61B
IRIDEX Corporation (IRIX) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
IRIDEX Corporation (IRIX) is a medical devices company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported IRIX revenue for 2026-07-04 was $12.6M. Net income was -$1.3M. Revenue was up 6.5% from 2026-04-04 to 2026-07-04. IRIX currently screens at market cap $19.0M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
IRIX currently screens at market cap $19.0M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the IRIX and PATH stock pages for the full models.
Not investment advice.